Duality Advisers, LP Blueprint Medicines Corp Transaction History

Duality Advisers, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 08, 2022	SELL	$45.23 - $70.15 $539,005 - $835,977	-11,917 Closed	0 $0
Q1 2022 May 09, 2022	BUY	$54.1 - $110.08 $644,709 - $1.31 Million	11,917 New	11,917 $761,000
Q3 2021 Nov 08, 2021	SELL	$80.98 - $109.47 $793,280 - $1.07 Million	-9,796 Closed	0 $0
Q2 2021 Aug 09, 2021	BUY	$82.78 - $101.0 $810,912 - $989,396	9,796 New	9,796 $862,000
Q1 2021 May 13, 2021	SELL	$90.71 - $108.28 $439,489 - $524,616	-4,845 Closed	0 $0
Q4 2020 Feb 09, 2021	BUY	$92.08 - $124.48 $446,127 - $603,105	4,845 New	4,845 $543,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Duality Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Duality Advisers, LP with notifications on news.